Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ivan Cherrez Ojeda (Guayaquil, Ecuador), Ivan Cherrez Ojeda, Vincent Cottin, Juan Calderon, Erick Calero, Dayana Cabrera, Annia Cherrez, Jose Martin Vilema. Diagnosis, treatment and attitudes about idiopathic pulmonary fibrosis in Latin American physicians. Eur Respir J 2016; 48: Suppl. 60, 2085

Member's Comments

No comment yet.

Related content which might interest you: Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Development of the interstitial lung disease multidiciplinary team meeting 2005-2013 Source: International Congress 2015 – Kaleidoscope of nursing research Year: 2015 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 The value of a specialist nurse-lead interstitial lung disease clinic, patients’ views Source: International Congress 2015 – Kaleidoscope of nursing research Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Can current guidelines improve the diagnosis of a usual interstitial pneumonia among general radiologists? Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey Source: International Congress 2016 – IPF clinical Year: 2016 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity Source: Eur Respir J 2016; 48: 282-283 Year: 2016 European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity Source: Eur Respir J 2016; 48: 283-284 Year: 2016 Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines Source: Eur Respir Rev 2014; 23:193-214 Year: 2014 Clinical highlights from the 2011 ERS Congress in Amsterdam Source: Eur Respir J 2012; 39: 1501-1510 Year: 2012